Literature DB >> 15807715

Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003.

H B Krentz1, G Kliewer, M J Gill.   

Abstract

OBJECTIVES: To examine changes over a 2-year period in both the mortality rate and the causes of death in a geographically defined HIV-infected population.
METHODS: A database search of primary care information for the dates and causes of death for all patients documented with HIV infection and living in Southern Alberta between 1984 and 2003 was undertaken. Sociodemographic and clinical characteristics were obtained. Causes of death were then individually confirmed by reviewing the patients' hospital charts, autopsy reports, or death certificates and coded using the International Classification of Diseases, 9th Revisions. AIDS deaths were reconciled with Public Health Reports. The time span was divided into pre-highly active antiretroviral therapy (HAART) (1984-1996) and current HAART (1997-2003) periods.
RESULTS: Between 1984 and 2003, there were 560 deaths in the 1987 individuals living with HIV infection in Southern Alberta. Of these, 436 deaths (78%) occurred pre-HAART and 124 (22%) in the current HAART period. The crude mortality rate declined from 117 deaths per 1000 patient-years pre-HAART to 24 in the current HAART period. In the pre-HAART era, 90% of all deaths were AIDS related whereas only 67% were AIDS related in the current HAART era. The leading causes of AIDS deaths were AIDS multiple causes (31%), Mycobacterium avium complex (18%), Pneumocystis pneumonia (10%) and non-Hodgkin's lymphoma (7%). The proportion of non-AIDS related deaths increased from 7% pre-HAART to 32% in the current HAART era. Accidental deaths, including drug overdose (29%), suicide (7%) and violence (3%), hepatic disease (19%), non-AIDS related malignancies (19%), and cardiovascular disease (16%) accounted for the majority of non-AIDS related deaths. No deaths directly caused by drug toxicity were found. Overall, 21% of patients who died were antiretroviral (ARV)-naive. A total of 14% of patients dying from AIDS were ARV-naive in contrast to 35% dying from non-HIV related conditions. Of all those dying from AIDS, 23% died<3 months after their initial diagnosis, reflecting late presentation. In the current HAART era, 87% of patients who died from AIDS were extensively treated, reflecting HAART treatment failures due mostly to multiclass drug resistance (42%), inexorable disease progression despite ARV (32%), lack of ability or interest to be maintained on a lifelong HAART programme (21%) and, rarely, drug intolerance (<1%).
CONCLUSIONS: Deaths from AIDS-related causes have decreased significantly, but deaths from non-AIDS related conditions have increased, both as an absolute number of deaths and as a proportion of all deaths in HIV-infected patients. The increasing age of the HIV population, and the increased mean CD4 count, increased proportion of intravenous drug users, increased hepatitis B virus and hepatitis C virus coinfection rate, and increased history of smoking seen in our population also influenced the mortality rate and causes of death. These factors must also be considered in projecting future trends in mortality of an HIV-infected population.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15807715     DOI: 10.1111/j.1468-1293.2005.00271.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  77 in total

1.  Safety and tolerability of varenicline tartrate (Champix(®)/Chantix(®)) for smoking cessation in HIV-infected subjects: a pilot open-label study.

Authors:  Qu Cui; Linda Robinson; Dawn Elston; Fiona Smaill; Jeffrey Cohen; Corinna Quan; Nancy McFarland; Lehana Thabane; Andrew McIvor; Johannes Zeidler; Marek Smieja
Journal:  AIDS Patient Care STDS       Date:  2011-10-18       Impact factor: 5.078

2.  Trends in CD4 cell count response to first-line antiretroviral treatment in HIV-positive patients from Asia, 2003-2013: TREAT Asia HIV Observational Database Low Intensity Transfer.

Authors:  Nicole L De La Mata; Penh S Ly; Oon T Ng; Kinh V Nguyen; Tuti P Merati; Thuy T Pham; Man P Lee; Jun Y Choi; Annette H Sohn; Matthew G Law; Nagalingeswaran Kumarasamy
Journal:  Int J STD AIDS       Date:  2017-03-21       Impact factor: 1.359

3.  Solid organ transplantation and HIV: A changing paradigm.

Authors:  Bl Johnston; Jm Conly
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-11       Impact factor: 2.471

Review 4.  Periodontal and other oral manifestations of immunodeficiency diseases.

Authors:  M E Peacock; R M Arce; C W Cutler
Journal:  Oral Dis       Date:  2016-10-10       Impact factor: 3.511

5.  An observational case series of HIV-positive patients treated with open reduction internal fixation for a closed lower extremity fracture.

Authors:  Jiandong Hao; Benoit Herbert; Juan C Quispe; Derly O Cuellar; Vivek Chadayammuri; Ji Wan Kim; Heather Young; Mark E Hake; Mark E Hammerberg; David J Hak; Cyril Mauffrey
Journal:  Eur J Orthop Surg Traumatol       Date:  2015-02-04

Review 6.  Review: thromboses among HIV-infected patients during the highly active antiretroviral therapy era.

Authors:  Nancy F Crum-Cianflone; Jhamillia Weekes; Mary Bavaro
Journal:  AIDS Patient Care STDS       Date:  2008-10       Impact factor: 5.078

7.  Characteristics of colorectal cancer in the human immunodeficiency virus-infected African American population.

Authors:  Avishek Kumar; Nihar Shah; Yashpal Modi; Hamid S Shaaban; Joseph DePasquale; Vincent A DeBari; Swaroopa Yerrabothala; Michael Maroules; Gunwant K Guron
Journal:  Med Oncol       Date:  2011-06-28       Impact factor: 3.064

8.  Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality.

Authors:  Angie N Pinto; Pat Grey; Ansari Shaik; David A Cooper; Anthony D Kelleher; Kathy Petoumenos
Journal:  AIDS Res Hum Retroviruses       Date:  2018-07-17       Impact factor: 2.205

9.  Risk of cardiovascular disease in HIV, hepatitis C, or HIV/hepatitis C patients compared to the general population.

Authors:  L Kakinami; R C Block; M J Adams; S E Cohn; B Maliakkal; S G Fisher
Journal:  Int J Clin Pract       Date:  2013-01       Impact factor: 2.503

10.  Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study.

Authors:  Vincent C Marconi; Greg A Grandits; Amy C Weintrob; Helen Chun; Michael L Landrum; Anuradha Ganesan; Jason F Okulicz; Nancy Crum-Cianflone; Robert J O'Connell; Alan Lifson; Glenn W Wortmann; Brian K Agan
Journal:  AIDS Res Ther       Date:  2010-05-27       Impact factor: 2.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.